Radius Health, Inc.

Radius Health, Inc.

Radius Health, Inc.

Overview
Date Founded

2003

Type of Company

Public

Employees (Worldwide)

383

Industries

Biotechnology
Hospitals & Patient Services
IT Consulting & Services
Medical Support Services

Company Description

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

Contact Data
Trying to get in touch with decision makers at Radius Health, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer, Treasurer & Chief Accounting Officer

Chief Commercial Officer

Chief Business Officer

Chief Medical Officer & Head of Discovery Science

Head of Oncology

Vice President, Finance

Executive Director & Head of Clinical Development-Abaloparatide Program

Board of Directors

Executive Partner at MPM Capital Inc

Operating Partner at Advent International LLC

Vice President Revenue Cycle at Trinity Mother Frances Health System

Professor & Executive Director-Personalized Health at University of Utah Health Sciences Center

Executive Vice President at Malin Corp. Plc

Fund Advisor at Altaba, Inc. (Investment Company)

President & Chief Executive Officer at Radius Health, Inc.

Director & Secretary at The North Carolina Biotechnology Center

Paths to Radius Health, Inc.
Potential Connections via
Relationship Science
You
Radius Health, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Details Hidden

Rubric Capital Management aims to achieve capital appreciation and maximize risk-adjusted absolute returns. The firm employs a value-oriented long/short strategy comprised of, but not limited to, a book of deep-value long positions and an alpha short book that is core to its strategy. They utilize a fundamental and multi-year perspective in identifying the core investments from a universe generally comprised of equities and debt in all sectors. Furthermore, the firm implements a disciplined approach to risk management and capital preservation at the position, portfolio and firm levels in seeking to maximize the delivery of alpha from both its long and short investments.

Recent Transactions
Details Hidden

Teijin Ltd. purchases Radius Health, Inc. /Abaloparatide-SC Asset from Radius Health, Inc.

Details Hidden

Radius Health, Inc. issued USD Common Stock

Details Hidden

Radius Health, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onRadius Health, Inc. issued USD Common Stock

Legal Advisor

Advised onRadius Health, Inc. issued USD Common Stock

Underwriter

Advised onRadius Health, Inc. issued USD Common Stock

Legal Advisor

Advised onRadius Health, Inc. issued USD Common Stock

Managing Director

Advised onRadius Health, Inc. issued USD Common Stock

Managing Director

Advised onRadius Health, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Morgan, Lewis & Bockius LLP

Legal Advisor

Partner at Latham & Watkins LLP

Senior Advisor

Global Chief Commercial Officer at Ascendis Pharma A/S

Clients

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2019
Market Capitalization
$964M
Total Enterprise Value
$969M
Earnings Per Share
$-2.89
Net Profit
$-133M
EBITDA
$-110M
EBITDAMargin
-63.42%
Total Debt
$202M
Total Equity
$-42.3M
Enterprise Value / Sales
5.59x
TEVNet Income
-7.28x
Debt TEV
0.21x
Revenue
$173M
Investors
Details Hidden

Co-Founder at Torque Therapeutics, Inc.

Details Hidden

Senior Partner at Flagship Pioneering

Details Hidden

MPM invests in companies located in the US and across the globe. The firm focuses on companies that aim to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and health technology sector. They provide financing for early stage transactions.

Suppliers
Vetter Pharma-Fertigung GmbH & Co. KG Other Business & Consulting Services | Ravensburg, Germany

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start.The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities.Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

3M Company Computer Software | Saint Paul, Minnesota

3M Co. is a technology company, which manufactures industrial, safety and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment consists of electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Health Care segment includes medical and surgical supplies, skin health and infection prevention products, oral care solutions, separation and purification sciences, health information systems, inhalation and transdermal drug delivery systems, and food safety products. The Electronics & Energy segment involves in the optical films solutions for electronic displays, packaging and interconnection devices; insulating and splicing solutions; touch screens and touch monitors; renewable energy component solutions; and infrastructure protection products. The Consumer segment products includes office supply products, stationery products, home improvement products, home care products, protective material products, certain consumer retail personal safety products, and consumer health care products. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

Eisai Co., Ltd. Wholesale: Consumer Non-Durables/Sundries | Tokyo, Japan

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Competitors
Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Radius Health, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Radius Health, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Radius Health, Inc..